Gain Therapeutics initiates Phase 1b trial of GT-02287

Gain Therapeutics (GANX) announced it has received approval in Australia to initiate a Phase 1b trial. Gain will be working with local Parkinson’s disease, PD, advocacy groups to support enrollment and expects enrollment to complete in the spring of 2025 with data from the study expected mid-2025. GT-02287 is the Company’s lead allosteric small molecule in clinical development for the treatment of PD with or without a GBA1 mutation. The primary goal of the Phase 1b trial is to assess the safety and tolerability of GT-02287 in people with PD.